1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Actavia Life Sciences, Inc.

Actavia Life Sciences, Inc.

RASP
Actavia Life Sciences, Inc.US flagOther OTC
0.00
USD
- -
- -
385,906.00Market Cap
Actavia Life Sciences, Inc.
RASP
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
-0.01
-0.07
-0.06
-0.01
-0.08
-0.01
-0.01
-0.01
- -
Basic EPS, GAAP
- -
- -
- -
- -
-0.05
-0.04
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
-0.01
-0.15
-0.24
-0.25
-0.33
-0.34
-0.22
-0.05
-0.04
Book Value per Share
0.01
- -
- -
-0.01
0.04
-0.03
-0.03
-0.04
-0.04
-0.02
- -
- -
Tangible Book Value per Share
5
11
11
11
61
69
69
69
69
111
578
772
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
-4
-4
-1
-5
-1
-1
-4
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
3
-2
-2
-3
-3
-2
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
8
3
3
-3
-3
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
772
772
772
Market Capitalization
10
5
6

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'24
Mar'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1,059.22%
-48.72%
15.83%
Free Cash Flow
2,650.6%
0.18%
-97.28%
Net Income, GAAP
885.8%
167.15%
547.05%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
-0.01
- -
-0.01
2023
- -
-0.01
- -
- -
-0.01
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
EQRx, Inc. (EQRXW)
Purple Biotech Ltd. (PPBT.TA)
FamiCord AG (VTIAF)
PRISM BioLab Co.,LTD (206A.T)
Predictive Technology Group, Inc. (PRED)
IntelGenx Technologies Corp. (IGX.TO)
Business
Actavia Life Sciences, Inc. (RASP) is a leukemia-focused biotechnology company that develops small-molecule therapeutics targeting acute myeloid leukemia (AML), lymphoma, and other life-threatening blood cancers; its lead product candidates include RASP-201, a novel orally administered selective reversible inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) to restore cell differentiation in poor-prognosis AML, and RASP-301, a preclinical nucleophosmin (NPM1) inhibitor designed for refractory AML with reduced toxicity. The company operates in the oncology and hematology segments, serving patient populations with high unmet needs in blood cancer treatments through enhanced combination therapies. Founded in 2013 and headquartered at 5 Penn Plaza in New York, NY, with research facilities in Doylestown, Pennsylvania, Actavia conducts its activities primarily in the United States and maintains a London office for international outreach. In October 2023, the company changed its name from Rasna Therapeutics, Inc. to Actavia Life Sciences, Inc. to reflect its strategic evolution in life sciences while retaining its core focus on leukemia therapeutics. It continues preclinical and early clinical advancement of its pipeline amid ongoing losses, with recent earnings for the six months ended March 31, 2024, reflecting operational expenses without revenue generation. No major acquisitions, partnerships, or funding rounds have been announced in the past two years.